Table 1.
Summary results of phase II and III studies evaluating the effect of rapalogs as a single agent in the treatment of refractory/relapsed NH B-cell lymphomas.
| Disease | Drug name | Trial phase | Nbe of patients in the cohort | Dose administrated | ORR (%) | CR (%) | DR (months) | References | Year of publication |
|---|---|---|---|---|---|---|---|---|---|
| MCL | Temsirolimus | II | 35 | 250 mg weekly | 38 | 3 | 6.9 | (78) | 2005 |
| MCL | Temsirolimus | II | 29 | 25 mg weekly | 41 | 3.7 | 6 | (79) | 2008 |
| MCL | Temsirolimus | III | 162 | 175 mg weekly (for 3 weeks) followed by 75 or 25 mg weekly | 22 (175/75 mg) 6 (175/25 mg) 2 (IC) | 2 (175/75 mg) 0 (175/25 mg) 2 (IC) | 7.1 (175/75 mg) 3.6 (175/25 mg) NA (IC) | (80) | 2009 |
| MCL | Everolimus | II | 19 | 10 mg daily | 32 | 10.5 | NA | (81) | 2011 |
| MCL | Everolimus | II | 35 | 10 mg daily | 20 | 6 | 5.5 | (82) | 2012 |
| DLBCL | Temsirolimus | II | 32 | 25 mg | 28 | 12.5 | 7.2 | (83) | 2010 |
| DLBCL | Everolimus | II | 47 | 10 mg daily | 30 | 0 | NA | (81) | 2011 |
| FL | Temsirolimus | II | 39 | 25 mg | 54 | 25 | 12.5 | (83) | 2010 |
| FL | Everolimus | II | 8 | 10 mg daily | 38 | 12.5 | NA | (81) | 2011 |
ORR, overall response rate; CR, complete response; DR, duration response; MCL, Mantle Cell Lymphoma; DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma; IC, investigator's choice; NA, not available.